Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia

References

• Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom’s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood. 1994;83(10):2939–2945.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30(2):110–115.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol. 2000;18(1):214–226.
   PubMed Web of Science ®Google Scholar
• Paulus A, Akhtar S, Caulfield TR, et al. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016;6(11):e492.
   PubMed Web of Science ®Google Scholar
• Chitta K, Paulus A, Akhtar S, et al. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015;169(3):377–390.
   PubMed Web of Science ®Google Scholar
• Paulus A, Ailawadhi S, Chanan-Khan A. Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol. 2016;29(2):216–228.
   PubMed Web of Science ®Google Scholar
• Bassermann F, Eichner R, Pagano M. The ubiquitin proteasome system – implications for cell cycle control and the targeted treatment of cancer. Biochim Biophys Acta. 2014;1843(1):150–162.
   PubMed Web of Science ®Google Scholar
• Devine T, Dai MS. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy. Curr Pharm Des. 2013;19(18):3248–3262.
   PubMed Web of Science ®Google Scholar
• Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15(3):933–942.
   PubMed Web of Science ®Google Scholar
• Jin L, Tabe Y, Kojima K, et al. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett. 2010;299(2):161–170.
   PubMed Web of Science ®Google Scholar
• Saha MN, Jiang H, Jayakar J, et al. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther. 2010;9(11):936–944.
   PubMed Web of Science ®Google Scholar
• Ooi MG, Hayden PJ, Kotoula V, et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009;15(23):7153–7160.
   PubMed Web of Science ®Google Scholar
• Treon SP, Hunter ZR, Matous J, Joyce RM, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom’s macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res. 2007;13(11):3320–3325.
   PubMed Web of Science ®Google Scholar
• Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016 . JAMA Oncol. 2017;3(9):1257–1265.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010;28(8):1422–1428.
   PubMed Web of Science ®Google Scholar
• Chen CI, National Cancer Institute of Canada Clinical Trials Group, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(12):1570–1575.
   PubMed Web of Science ®Google Scholar
• Broyl A, Jongen JL, Sonneveld P. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma. Semin Hematol. 2012;49(3):249–257.
   PubMed Web of Science ®Google Scholar
• Meregalli C. An overview of bortezomib-induced neurotoxicity. Toxics. 2015;3(3):294–303.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Mondal SK, Mukhopadhyay D, et al. Development of liposomal formulation for delivering anticancer drug to breast cancer stem-cell-like cells and its pharmacokinetics in an animal model. Mol Pharm. 2016;13(3):1081–1088.
   PubMed Web of Science ®Google Scholar
• Chitta K, Paulus A, Caulfield TR, et al. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014;4:e260.
   PubMed Web of Science ®Google Scholar
• Paulus A, Manna A, Akhtar S, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. Br J Haematol. 2018;183(2):196–211.
   PubMed Web of Science ®Google Scholar
• Manna A, De Sarkar S, De S, et al. The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance. Phytomedicine. 2015;22(7-8):713–723.
   PubMed Web of Science ®Google Scholar
• Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21(11):1318–1325.
   PubMed Web of Science ®Google Scholar
• Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59(11):2615–2622.
   PubMed Web of Science ®Google Scholar
• Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8(4):333–338.
   PubMed Web of Science ®Google Scholar
• Miyachi M, Kakazu N, Yagyu S, et al. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells. Clin Cancer Res. 2009;15(12):4077–4084.
   PubMed Web of Science ®Google Scholar
• Poulain S, Roumier C, Bertrand E, et al. TP53 mutation and its prognostic significance in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2017;23(20):6325–6335.
   PubMed Web of Science ®Google Scholar
• Ailawadhi S, Paulus A, Chanan-Khan A. Preclinical models of Waldenström's macroglobulinemia and drug resistance. Best Pract Res Clin Haematol. 2016;29(2):169–178.
   PubMed Web of Science ®Google Scholar
• Chitta KS, Paulus A, Ailawadhi S, et al. Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute – Waldenström Macroglobulinemia 1. Leuk Lymphoma. 2013;54(2):387–396.
   PubMed Web of Science ®Google Scholar
• Fouty B, Moss T, Solodushko V, et al. Dexamethasone can stimulate G1-S phase transition in human airway fibroblasts in asthma. Eur Respir J. 2006;27(6):1160–1167.
   PubMed Web of Science ®Google Scholar
• Mattern J, Buchler MW, Herr I. Cell cycle arrest by glucocorticoids may protect normal tissue and solid tumors from cancer therapy. Cancer Biol Ther. 2007;6(9):1345–1354.
   PubMed Web of Science ®Google Scholar
• Sharma S, Lichtenstein A. Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors. Blood. 2008;112(4):1338–1345.
   PubMed Web of Science ®Google Scholar
• Greenstein S, Ghias K, Krett NL, et al. Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies. Clin Cancer Res. 2002;8(6):1681–1694.
   PubMed Web of Science ®Google Scholar
• Daoud SS, Juliano RL. In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and ras-transformed 3T3 cells. Cancer Chemother Pharmacol. 1989;23(3):151–155.
   PubMed Web of Science ®Google Scholar
• Bohlman S, Manfredi JJ. p53-independent effects of Mdm2. Subcell Biochem. 2014;85:235–246.
   PubMedGoogle Scholar